Related Experiment Video
Updated: May 21, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
Published on: May 11, 2018
Left ventricular assist devices in heart failure
1Division of Cardiac Surgery, The Ohio State University, N-831 Doan Hall, 410 W. 10th Avenue, Columbus, OH, USA.
Insights
Left ventricular assist devices (LVADs) significantly improve survival for end-stage heart failure patients, offering a vital alternative to transplantation. These advanced devices enhance quality of life and reduce complications compared to earlier models.
Area of Science:
- Cardiovascular Medicine
- Medical Devices
- Surgical Technology
Background:
- End-stage heart failure presents a critical unmet medical need with limited survival options.
- Historically, heart transplantation was the sole definitive treatment for advanced heart failure.
- The development of left ventricular assist devices (LVADs) emerged from the necessity to support patients awaiting transplantation.
Purpose of the Study:
- To review landmark studies validating LVADs as a primary therapeutic option for heart failure.
- To provide an overview of currently available LVAD technologies.
- To discuss future advancements and innovations in LVAD therapy.
Main Methods:
- Review of pivotal clinical trials and research demonstrating the efficacy of LVADs.
- Analysis of data comparing outcomes between different generations of LVADs.
- Synthesis of current literature on LVAD technology and patient management.
Main Results:
- LVADs have quadrupled survival rates in patients with end-stage heart failure.
- Modern LVADs exhibit improved biocompatibility, reduced perioperative morbidity, and extended device longevity.
- LVADs have fundamentally transformed the treatment paradigm for advanced heart failure.
Conclusions:
- LVADs represent a significant therapeutic advancement, dramatically improving survival and quality of life for heart failure patients.
- Ongoing technological progress in LVADs promises further enhancements in patient outcomes.
- LVADs are now an established and indispensable component of advanced heart failure management.
Abstract:
End-stage heart failure is an ever-growing and devastating disease. The median survival for patients with heart failure on ionotropic support alone is a meager 6 months. Historically, the only option for these patients was to be listed for heart transplantation. Out of medical necessity, the idea of left ventricular assist device (LVAD) as a bridge to transplantation was born. Since their approval by the US FDA, LVADs have quadrupled the survival in patients with heart failure. The increase in survival has also been accompanied by decreased perioperative morbidity, better biocompatibility and longer device life over first-generation LVADs. Undoubtedly, LVADs have changed the landscape of heart failure treatment and will continue to do so in the foreseeable future. In this review, we will highlight the landmark studies that have established LVADs as a therapeutic option for heart failure, as well as reviewing the current LVADs available and speculating on the advancements that will be made in the upcoming years.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Cardiomyopathy V: Interprofessional Care
Heart Failure V: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure Drugs: Inotropic Agents
Heart Failure IV: Classification and Diagnostic Evaluation
